Targeting the proteasome as a promising therapeutic strategy in thyroid cancer

Journal of Surgical Oncology

Volumn 105, Issue 4, 2012, Pages 357-364

  Wunderlich, Annette ^a   Arndt, Tjadina ^a   Fischer, Melina ^a   Roth, Silvia ^a   Ramaswamy, Annette ^b   Greene, Brandon H ^c   Brendel, Cornelia ^b   Hinterseher, Ulrike ^a   Bartsch, Detlef K ^a   Hoffmann, Sebastian ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

mitotic arrest; proteasome inhibitors; thyroid cancer; xenotransplantation

Indexed keywords

BORTEZOMIB; CASPASE 3; CD31 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PROTEASOME;

ANAPLASTIC CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CARCINOMA; CARCINOMA, PAPILLARY; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84857046133     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22113     Document Type: Article

References (48)

1. Davies L, Welch HG,: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-2167.
2. McIver B, Hay ID, Giuffrida DF, et al.: Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 2001; 130: 1028-1104.
3. Caron NR, Clark OH,: Well differentiated thyroid cancer. Scand J Surg 2004; 93: 261-271. Review. (Pubitemid 40095952)
4. Diehl S, Umbricht CB, Dackiw AP, et al.: Modern approaches to age-old questions about thyroid tumors. Thyroid 2005; 15: 575-582. Review. (Pubitemid 40993731)
5. Ain KB, Tofiq S, Taylor KD,: Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 1999; 81: 3650-3653.
6. Pasieka JL,: Anaplastic thyroid cancer. Curr Opin Oncol 2003; 15: 78-83. Review. (Pubitemid 36135652)
7. Ciechanover A,: The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13-21. (Pubitemid 24309509)
8. Adams J, Palombella VJ, Sausville EA, et al.: Proteasome inhibitors: A novel cl.: Antitumor agents. Cancer Res 1999; 59: 2615-2622. (Pubitemid 29269108)
9. Wu WK, Cho CH, Lee CW, et al.: Proteasome inhibition: A new therapeutic strategy to cancer treatment. Cancer Lett 2010; 293: 15-22.
10. Einsele H,: Bortezomib. Recent Results Cancer Res 2010; 184: 173-187.
11. Mitsiades CS, McMillin D, Kotoula V, et al.: Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 2006; 91: 4013-4021. (Pubitemid 44536879)
12. Conticello C, Adamo L, Giuffrida R, et al.: Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab 2007; 92: 1938-1942. (Pubitemid 46997213)
13. Mitsiades CS, Hayden P, Kotoula V, et al.: Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. J Clin Endocrinol Metab 2007; 92: 4845-4852. (Pubitemid 350223468)
14. Du ZX, Zhang HY, Meng X, et al.: Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer 2009; 16: 56.
15. Wang HQ, Du ZX, Zhang HY, et al.: Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells. Endocrinology 2007; 148: 3258-3270.
16. Stenner F, Liewen H, Zweifel M, et al.: Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci 2008; 99: 1847-1852.
17. Ishizaka Y, Ushijima T, Sugimura T, et al.: cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line. Biochem Biophys Res Commun 1990; 168: 402-408. (Pubitemid 20164556)
18. Hoelting T, Zielke A, Siperstein AE, et al.: Abberations of growth factor control in metastatic follicular thyroid cancer in vitro. Clin Exp Metastasis 1994; 12: 315-323. (Pubitemid 24257069)
19. Heldin NE, Westermark B,: The molecular biology of the human anaplastic thyroid carcinoma cell. Thyroidology 1991; 3: 127-131.
20. Hoffmann S, Burchert A, Wunderlich A, et al.: Differential effects of cetuximab and AEE788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine 2007; 31: 105-113. (Pubitemid 350195142)
21. Wunderlich A, Fischer M, Schloßhauer T, et al.: Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer. Cancer Sci 2011; 102: 762-768.
22. Barth PJ, Weingärtner K, Köhler HH, et al.: Assessment of vascularization in prostatic carcinoma: a morphometric investigation. Human Pathol 1996; 27: 1306-1310. (Pubitemid 26415324)
23. Hoffmann S, Rockenstein A, Ramaswamy A, et al.: Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol Cell Endocrinol 2007; 264: 74-81. (Pubitemid 46097303)
24. Baiz D, Pozzato G, Dapas B, et al.: Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 2009; 91: 373-382.
25. Wang Y, Rishi AK, Puliyappadamba VT, et al.: Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol 2010; 66: 455-466.
26. Codony-Servat J, Tapia MA, Bosch M, et al.: Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006; 5: 665-675.
27. Mitsiades N, Mitsiades CS, Richardson PG, et al.: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003; 101: 2377-2380. (Pubitemid 36302084)
28. Ling YH, Liebes L, Jiang JD, et al.: Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9: 1145-1154. (Pubitemid 36323724)
29. Gordon GJ, Mani M, Maulik G, et al.: Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008; 61: 549-558.
30. Zavrski I, Jakob C, Kaiser M, et al.: Molecular and clinical aspects of proteasome inhibition in the treatment of cancer. Recent Results Cancer Res 2007; 176: 165-176. Review.
31. Maki CG, Huibregtse JM, Howley PM,: In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996; 56: 2649-2654. (Pubitemid 26170702)
32. Nickeleit I, Zender S, Sasse F, et al.: Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008; 14: 23-35. (Pubitemid 351885496)
33. Sayers TJ, Murphy WJ,: Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006; 55: 76-84. Review. (Pubitemid 41783297)
34. Saulle E, Petronelli A, Pasquini L, et al.: Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 2007; 12: 635-655. (Pubitemid 46411475)
35. Liu J, Qu XJ, Xu L, et al.: Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells. Dig Dis Sci 2010; 55: 3361-3368.
36. Seki N, Toh U, Sayers TJ, et al.: Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Ther 2010; 9: 1842-1851.
37. Chen KF, Yeh PY, Hsu C, et al.: Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009; 284: 11121-11133.
38. Boccadoro M, Morgan G, Cavenagh J,: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005; 5: 18.
39. Dolcet X, Llobet D, Encinas M, et al.: Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 2006; 281: 22118-22130. (Pubitemid 44181916)
40. Markovina S, Callander NS, O'Connor SL, et al.: Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 2008; 6: 1356-1364.
41. Hideshima T, Ikeda H, Chauhan D, et al.: Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009; 114: 1046-1052.
42. Mitsiades N, Mitsiades CS, Poulaki V, et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374-14379. (Pubitemid 35257679)
43. Williamson MJ, Silva MD, Terkelsen J, et al.: The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol Cancer Ther 2009; 8: 3234-3243.
44. Williams S, Pettaway C, Song R, et al.: Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003; 2: 835-843.
45. Roccaro AM, Hideshima T, Raje N, et al.: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66: 184-191. (Pubitemid 43166024)
46. Birle DC, Hedley DW,: Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 2007; 67: 1735-1743. (Pubitemid 46383400)
47. Tamura D, Arao T, Tanaka K, et al.: Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci 2010; 101: 1403-1408.
48. Bauerle KT, Schweppe RE, Haugen BR,: Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer 2010; 21: 117.